Argatroban A New Treatment Option for Heparin-Induced Thrombocytopenia

Cleveland, Kevin W.
December 2003
Critical Care Nurse;Dec2003, Vol. 23 Issue 6, p61
Academic Journal
Presents a study which focused on argatroban, a treatment option for heparin-induced thrombocytopenia (HIT). Definition of HIT; Therapeutic alternatives; Inforamation on danaparoid sodium, an alternative to heparin for treating patients with HIT.


Related Articles

  • Heparin-induced thrombocytopenia costly for US hospitals.  // PharmacoEconomics & Outcomes News;1/14/2006, Issue 494, p5 

    The article discusses research being done on the financial impact of heparin-induced thrombocytopenia. It references a study by M. A. Smythe and colleagues published in the November 16, 2005 issue of "Blood" journal. The results show that substituting heparin for alternative anticoagulants...

  • The Direct Medical Costs Associated with Suspected Heparin-Induced Thrombocytopenia. Nanwa, Natasha; Mittmann, Nicole; Knowles, Sandra; Bucci, Claudia; Selby, Rita; Shear, Neil; Walker, Scott E.; Geerts, William // PharmacoEconomics;2011, Vol. 29 Issue 6, p511 

    Background: Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction associated with heparin exposure. Sunnybrook Health Sciences Centre, a tertiary-care adult academic hospital, has cared for an average of 100 cases of suspected HIT per year. Although the management of suspected HIT...

  • Heparin-induced thrombocytopenia costly for US hospitals.  // Reactions Weekly;1/21/2006, Issue 1085, p3 

    The article presents the results of a study on the evaluation of length of stay, total costs and reimbursement associated with a diagnosis of heparin-induced thrombocytopenia. It mentions the possible outcome of substituting heparin for alternative anticoagulants. Difference between the length...

  • Heparin.  // Reactions Weekly;1/11/2014, Issue 1483, p50 

    The article presents a case report on the adverse reaction of heparin to a 51-year-old man who developed heparin-induced thrombocytopenia and left ventricular (LV) thrombus after receiving the treatment.

  • Heparin.  // Reactions Weekly;Aug2015, Vol. 1563 Issue 1, p115 

    The article presents a case study of an 84-year-old man who developed thrombocytopenia while receiving heparin.

  • Treatment options for heparin-induced thrombocytopenia. Greinacher, Andreas // American Journal of Health-System Pharmacy;10/15/2003 Supplement 5, Vol. 60, pS12 

    Appropriate management, as well as efficacy and safety, of heparin- induced thrombocytopenia (HIT) and prevention of severe consequences with argatroban and lepirudin are discussed. Heparin-induced thrombocytopenia, a serious immune-mediated drug reaction, can occur as an isolated incident...

  • A case of probable bemiparin-induced heparin-induced thrombocytopenia type II managed with low-dose fondaparinux. Koul, A. N.; Koufakis, T.; Tsapakidis, K.; Margaritis, A.; Gabranis, I. // Journal of Postgraduate Medicine;Oct-Dec2015, Vol. 61 Issue 4, p267 

    A letter to the editor is presented in response to the article "A Case of Probable Hemiparin-Induced Heparin-Induced Thrombocytopenia (HIT) Type II Managed With Low-Dose Fondaparinux" published in a previous issue.

  • Evaluation of a Standardized Protocol Using Lepirudin or Argatroban for Heparin-Induced Thrombocytopenia. Kennedy, Kenneth; Steinke, Doug; King, Shawn; Poe, Kevin; Reeves, Jordan; Short, Marintha // Cardiovascular & Hematological Agents in Medicinal Chemistry;2011, Vol. 9 Issue 4, p262 

    Study Objective: To evaluate the effectiveness of our institution's heparin-induced thrombocytopenia (HIT) protocol in achieving a therapeutic activated partial thromboplastin time (aPTT) and to evaluate patient outcomes related to bleeding and thrombotic events before and after protocol...

  • Argatroban Anticoagulation for Heparin-Induced Thrombocytopenia in Elderly Patients. Bartholomew, John R.; Pietrangeli, Carolynn E.; Hursting, Marcie J. // Drugs & Aging;2007, Vol. 24 Issue 6, p489 

    Background: Argatroban, a direct thrombin inhibitor that has reduced clearance in elderly versus younger volunteers, is used for thromboprophylaxis or treatment in heparin-induced thrombocytopenia (HIT). Objective: To evaluate the effect of aging on argatroban therapy, including dosage,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics